The importance of testing PET-directed therapy in patients with Hodgkin Lymphoma

Current Hematologic Malignancy Reports

Volumn 6, Issue 3, 2011, Pages 155-156

  Armitage, James O ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER THERAPY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL (TOPIC); DISEASE SEVERITY; FOLLOW UP; HODGKIN DISEASE; HUMAN; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; REVIEW; SECOND CANCER; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; HODGKIN DISEASE; HUMANS; POSITRON-EMISSION TOMOGRAPHY;

EID: 80055061887     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-011-0092-z     Document Type: Review

References (6)

1. Peters MV, Middlemiss KC. A study of Hodgkin's disease treated by irradiation. Am J Roentgenol Radium Ther Nucl Med. 1958;79 (1):114-21.
2. Kaplan HS. The radical radiotherapy of regionally localized Hodgkin's disease. Radiology. 1962;78:553-61.
3. DeVita Jr VT, Serpick AA, Carbone PP. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med. 1970;73(6):881-95.
4. Armitage JO. Early-stage Hodgkin's lymphoma. N Engl J Med. 2010;363(7):653-62.
5. Sher DJ, Mauch PM, Van Den Abbeele A, LaCasce AS, Czerminski J, Ng AK. Prognostic significance of mid- and post-ABVD PET imaging in Hodgkin's lymphoma: the importance of involved-field radiotherapy. Ann Oncol. 2009;20(11):1848-53.
6. Barnes J, LaCasce A, Toomey C, et al. Early interim FDG-PETscan predicts outcome in non-bulky limited stage Hodgkin lymphoma, but may not guide use of consolidative radiotherapy [abstract]. Blood. 2008;112:518.